6-K - GSK plc (0001131399) (Filer)
SEC · EDGAR 财务披露 · October 14, 2026 at 11:42 AM ET
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2026
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the ‘Company’)
Transaction notification
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) |
||||
|
a) |
Name |
Luke Miels |
|||
|
b) |
Position/status |
Chief Executive Officer |
|||
|
c) |
Initial notification/amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
||
|
£17.3550 |
756 |
||||
|
£17.3550 |
379 |
||||
|
£17.3550 |
278 |
||||
|
d) |
Aggregated information Aggregated volume Price |
1,413 £17.3550 |
|||
|
e) |
Date of the transaction |
2026-10-12 |
|||
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) |
||||
|
a) |
Name |
Julie Brown |
|||
|
b) |
Position/status |
Chief Financial Officer |
|||
|
c) |
Initial notification/amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
||
|
£17.3550 |
607 |
||||
|
£17.3550 |
707 |
||||
|
£17.3550 |
549 |
||||
|
d) |
Aggregated information Aggregated volume Price |
1,863 £17.3550 |
|||
|
e) |
Date of the transaction |
2026-10-12 |
|||
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) |
||||
|
a) |
Name |
James Ford |
|||
|
b) |
Position/status |
SVP and Group General Counsel, Legal and Compliance |
|||
|
c) |
Initial notification/amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
||
|
£17.3550 |
406 |
||||
|
£17.3550 |
246 |
||||
|
£17.3550 |
131 |
||||
|
d) |
Aggregated information Aggregated volume Price |
783 £17.3550 |
|||
|
e) |
Date of the transaction |
2026-10-12 |
|||
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) |
||||
|
a) |
Name |
Shobie Ramakrishnan |
|||
|
b) |
Position/status |
Chief Digital and Technology Officer |
|||
|
c) |
Initial notification/amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
American Depositary Shares (‘ADS’) ISIN: US37733W2044 |
|||
|
b) |
Nature of the transaction |
Increase in notional interest in ADS following the re-investment of dividends paid to shareholders on 8 October 2026 on ADS held in the Company’s Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
||
|
$46.5400 |
188 |
||||
|
$46.5400 |
113 |
||||
|
$46.5400 |
63 |
||||
|
d) |
Aggregated information Aggregated volume Price |
364 $46.5400 |
|||
|
e) |
Date of the transaction |
2026-10-12 |
|||
|
f) |
Place of the transaction |
New York Stock Exchange (XNYS) |
|||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) |
||||
|
a) |
Name |
David Redfern |
|||
|
b) |
Position/status |
President, Corporate Development |
|||
|
c) |
Initial notification/amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
||
|
£17.3550 |
481 |
||||
|
£17.3550 |
219 |
||||
|
£17.3550 |
194 |
||||
|
d) |
Aggregated information Aggregated volume Price |
894 £17.3550 |
|||
|
e) |
Date of the transaction |
2026-10-12 |
|||
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) |
||||
|
a) |
Name |
Regis Simard |
|||
|
b) |
Position/status |
President, Global Supply Chain |
|||
|
c) |
Initial notification/amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
||
|
£17.3550 |
579 |
||||
|
£17.3550 |
321 |
||||
|
£17.3550 |
203 |
||||
|
d) |
Aggregated information Aggregated volume Price |
1,103 £17.3550 |
|||
|
e) |
Date of the transaction |
2026-10-12 |
|||
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) |
||||
|
a) |
Name |
Philip Thomson |
|||
|
b) |
Position/status |
President, Global Affairs |
|||
|
c) |
Initial notification/amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
||
|
£17.3550 |
324 |
||||
|
£17.3550 |
195 |
||||
|
£17.3550 |
141 |
||||
|
d) |
Aggregated information Aggregated volume Price |
660 £17.3550 |
|||
|
e) |
Date of the transaction |
2026-10-12 |
|||
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) |
||||
|
a) |
Name |
Deborah Waterhouse |
|||
|
b) |
Position/status |
CEO, ViiV Healthcare and President, Global Health, GSK |
|||
|
c) |
Initial notification/amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
||
|
£17.3550 |
501 |
||||
|
£17.3550 |
302 |
||||
|
£17.3550 |
184 |
||||
|
d) |
Aggregated information Aggregated volume Price |
987 £17.3550 |
|||
|
e) |
Date of the transaction |
2026-10-12 |
|||
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) |
||||
|
a) |
Name |
Tony Wood |
|||
|
b) |
Position/status |
Chief Scientific Officer |
|||
|
c) |
Initial notification/amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan |
|||
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
||
|
£17.3550 |
618 |
||||
|
£17.3550 |
281 |
||||
|
£17.3550 |
258 |
||||
|
d) |
Aggregated information Aggregated volume Price |
1,157 £17.3550 |
|||
|
e) |
Date of the transaction |
2026-10-12 |
|||
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) |
||||
|
a) |
Name |
Maya Martinez-Davis |
|||
|
b) |
Position/status |
President, US |
|||
|
c) |
Initial notification/amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
American Depositary Shares ('ADS') ISIN: US37733W2044 |
|||
|
b) |
Nature of the transaction |
Acquisition of ADS following the re-investment of dividends paid to shareholders on 8 October 2026 |
|||
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
||
|
$46.5400 |
179.308 |
||||
|
d) |
Aggregated information Aggregated volume Price |
N/A (single transaction) |
|||
|
e) |
Date of the transaction |
2026-10-12 |
|||
|
f) |
Place of the transaction |
New York Stock Exchange (XNYS) |
|||
|
1. |
Details of PDMR/person closely associated with them (‘PCA’) |
||||
|
a) |
Name |
Julie Brown |
|||
|
b) |
Position/status |
Chief Financial Officer |
|||
|
c) |
Initial notification/amendment |
Initial notification |
|||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
GSK plc |
|||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
|
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63 |
|||
|
b) |
Nature of the transaction |
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Performance Share Plan subject to a 2-year holding period |
|||
|
c) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
||
|
£17.3550 |
2,409.639 |
||||
|
d) |
Aggregated information Aggregated volume Price |
N/A (single transaction) |
|||
|
e) |
Date of the transaction |
2026-10-12 |
|||
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|||
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
|
GSK plc |
|
|
(Registrant) |
|
|
Date: October 14, 2026 |
|
|
By:/s/ VICTORIA WHYTE -------------------------- |
|
|
Victoria Whyte |
|
|
Authorised Signatory for and on |
|
|
behalf of GSK plc |